American Journal of Clinical Dermatology

, Volume 10, Supplement 1, pp 7–12 | Cite as

Therapeutic Moisturizers as Adjuvant Therapy for Psoriasis Patients

  • Carlo Gelmetti
Review Article


At any point in time, psoriasis affects 2–3% of the world’s population and has one of the biggest impacts on quality of life of any dermatological disorder. Treatment is extremely costly and prevention of disease progression in severity and extent is crucial. Psoriasis treatment should include skin hydration (regular use of moisturizers and emollients), careful, gentle skin cleansing, and identification and avoidance of Koebner phenomenon triggers (excoriation, maceration) and infectious foci (Streptococcus pyogenes). Moisturizers have been shown to significantly improve skin conditions and quality of life for psoriasis patients. They are a valuable first-line treatment, as dry skin is common and adds to the irritability of the diseased skin. Most patients respond well to topical treatment with topical corticosteroids, emollients, coal tar, anthralin (dithranol) or calcipotriol. Emollients are the most prescribed products, providing transient relief from irritation and some possessing anti-inflammatory properties. Moisturizers and emollients should be used in the following cases: minimal psoriasis, napkin psoriasis, psoriasis of the folds, psoriatic skin damaged by previous local treatments, and in pregnancy or women of childbearing age.


Psoriasis Calcipotriol Acitretin Tazarotene Dithranol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Plunkett A, Marks R. A review of the epidemiology of psoriasis vulgaris in the community. Australas J Dermatol 1998; 39 (4): 225–32PubMedCrossRefGoogle Scholar
  2. 2.
    Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3 (2): 121–8PubMedCrossRefGoogle Scholar
  3. 3.
    Psoriasis statistics. National Psoriasis Foundation. 2007 [online]. Available from URL: [Accessed 2008 Jun 16]
  4. 4.
    Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 Suppl. 2: ii18–23; discussion ii4-5Google Scholar
  5. 5.
    Christophers E. Psoriasis: epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26 (4): 314–20PubMedCrossRefGoogle Scholar
  6. 6.
    Finzi AF, Benelli C. A clinical survey of psoriasis in Italy: 1st AISP report. Interdisciplinary Association for the Study of Psoriasis. J Eur Acad Dermatol Venereol 1998; 10 (2): 125–9CrossRefGoogle Scholar
  7. 7.
    Lew-Kaya D, Lue J, Sefton J, et al. Evaluating psoriasis severity: limitations of the PASI and advantages of the overall lesional assessment. J Am Acad Dermatol 2004; 50 (3 Suppl. 1): P153CrossRefGoogle Scholar
  8. 8.
    Leman J, Burden D. Psoriasis in children: a guide to its diagnosis and management Paediatr Drugs 2001; 3 (9): 673–80Google Scholar
  9. 9.
    Bos JD. Psoriasis, innate immunity, and gene pools. J Am Acad Dermatol 2007; 56 (3): 468–71PubMedCrossRefGoogle Scholar
  10. 10.
    Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6 (6): 383–92PubMedCrossRefGoogle Scholar
  11. 11.
    Pariser DM, Bagel J, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007; 143 (2): 239–42PubMedCrossRefGoogle Scholar
  12. 12.
    Janowski K, Steuden S. Severity of psoriasis and health-related quality of life: the moderating effects of temperament. Br J Dermatol 2008; 158 (3): 633–5PubMedCrossRefGoogle Scholar
  13. 13.
    Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 2003; 4 (11): 771–88PubMedCrossRefGoogle Scholar
  14. 14.
    Buraczewska I, Berne B, Lindberg M, et al. Changes in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial. Br J Dermatol 2007; 156 (3): 492–8PubMedCrossRefGoogle Scholar
  15. 15.
    Jackson EM. Latest information on how moisturizers work. Cosmet Dermatol 1992; 5: 35–7Google Scholar
  16. 16.
    Xhauflaire-Uhoda E, Haubrechts C, Pierard-Franchimont C, et al. Quality of life, emollients and hydrating agents. Rev Med Liege 2006; 61: 233–6PubMedGoogle Scholar
  17. 17.
    Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol 2008; 21 (2): 75–80PubMedCrossRefGoogle Scholar
  18. 18.
    Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc 2001; 76 (9): 943–9PubMedGoogle Scholar
  19. 19.
    Ghali FE. Improved clinical outcomes with moisturization in dermatologic disease. Cutis 2005; 76 (6 Suppl.): 13–8PubMedGoogle Scholar
  20. 20.
    Kynemund L, Jemec GB, Wulf HC. Moisturisers for psoriatic skin: do gross morphological differences matter? Skin Pharmacol Appl Skin Physiol 2001; 14 (1): 20–6PubMedGoogle Scholar
  21. 21.
    Nola I, Kostovic K, Kotrulja L, et al. The use of emollients as sophisticated therapy in dermatology. Acta Dermatovenerol Croat 2003; 11 (2): 80–7PubMedGoogle Scholar
  22. 22.
    Trapp M. Is there room for improvement in the emollients for adjuvant therapy? J Eur Acad Dermatol Venereol 2007; 21 Suppl. 2: 14–8PubMedCrossRefGoogle Scholar
  23. 23.
    Johnson A. Non-steroid skin cream in traumatic dermatoses: a clinical open evaluation. Med J Aust 1976; 1 (5): 111–3PubMedGoogle Scholar
  24. 24.
    Watsky KL, Freije L, Leneveu MC, et al. Water-in-oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis. Cutis 1992; 50 (5): 383–6PubMedGoogle Scholar
  25. 25.
    Melnik B, Braun-Falco O. The value of oil baths for adjuvant basic therapy of inflammatory dermatoses with dry, barrier-disrupted skin [in German]. Hautarzt 1996; 47 (9): 665–72PubMedCrossRefGoogle Scholar
  26. 26.
    Comaish JS, Greener JS. The inhibiting effect of soft paraffin on the Köbner response in psoriasis. Br J Dermatol 1976; 94 (2): 195–200PubMedCrossRefGoogle Scholar
  27. 27.
    Hagemann I, Proksch E. Topical treatment by urea reduces epidermal hyper-proliferation and induces differentiation in psoriasis. Acta Derm Venereol 1996; 76 (5): 353–6PubMedGoogle Scholar
  28. 28.
    Karvonen SL. Pregnancy and psoriasis: one disease and two persons [abstract no.W10]. 2nd International Congress on Psoriasis; 2007 Jun 21-24; ParisGoogle Scholar
  29. 29.
    Oren D, Nulman I, Makhija M, et al. Using corticosteroids during pregnancy: are topical, inhaled, or systemic agents associated with risk? Can Fam Physician 2004; 50: 1083–5PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Istituto di Scienze Dermatologiche, Fondazione IRCCS ‘Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena’MilanItaly

Personalised recommendations